PHA Canada Welcomes Federal Government Investment to Support Access to Rare Disease Drugs
The Pulmonary Hypertension Association of Canada Welcomes Federal Government Investment to Support Access to Rare Disease Drugs
Vancouver, British Columbia (March 22, 2023) - The Pulmonary Hypertension Association of Canada (PHA Canada) is pleased to see the announcement of $1.5 billion over three years in support of a National Strategy for Drugs for Rare Diseases. Most of this funding, $1.4 billion, will go to the provinces through bilateral, individualized agreements. As a critical next step to advance the development of these bilateral agreements, the Government of Canada will engage with provinces and territories to jointly determine a small set of new and emerging drugs that would be cost-shared and covered in a consistent way across the country.
“This is a good start. PHA Canada has long advocated for PH patients to receive equitable and timely access to optimal treatment options to manage their disease,” said Nicole Dempsey, Chair of PHA Canada’s Board of Directors. “The disparities that exist in the access to treatments PH patients may receive, depending on what province or territory they live in or whether they have private insurance, can significantly impact their quality of life and health outcomes. If the optimal treatments for pulmonary hypertension are included in the list of drugs publicly covered across Canada, it will go a long way to improving the lives of many people living with PH.”
The announcement included funding for research, improved data sharing for rare diseases, and establishing a stakeholder Implementation Advisory Group that will provide advice and continued engagement as the plan is unrolled. The Advisory Group, to be struck by Summer 2023, will comprise representatives of public and private drug plans, patients and clinicians, the pharmaceutical industry, and others.
What this means for Canadians living with pulmonary hypertension needs to be clarified. PHA Canada is encouraged by the proposed approach includes a patient input mechanism. We will be working to identify opportunities to have the voices of the PH community included in the process.
Background
Health Canada press release: https://lnkd.in/gR3A_3YJ
Canadian Organization for Rare Disorders (CORD) press release: bit.ly/3FDU3Ub
About Pulmonary Hypertension
Pulmonary hypertension—or PH—is a rare and very complex lung disease, which is progressive and potentially fatal. PH is characterized by high blood pressure in the pulmonary arteries (blood vessels) that carry blood to the lungs. PH means that the blood pressure in the arteries that carry blood to the lungs is too high. This excessive pressure is usually caused by restriction or blockage in the blood vessels. PH can cause the heart to work harder and lead to heart failure.
For more information, please visit: www.phacanada.ca/What-is-PH/About-PH
About the Pulmonary Hypertension Association of Canada (PHA Canada)
PHA Canada is a federally registered charity whose mission is to empower the Canadian pulmonary hypertension community through support, education, advocacy, awareness, and research. PHA Canada was established in 2008 by patients, caregivers, and healthcare professionals to work together to better the lives of Canadians affected by pulmonary hypertension and represent a united national PH community.
For more information about the Pulmonary Hypertension Association of Canada, please visit: www.phacanada.ca
— END —
The announcement of federal investment supporting access to rare disease medications is an encouraging development for patients and families facing complex healthcare challenges. Access to appropriate treatment can make a significant difference, particularly when conditions require specialized care and long term support. I appreciate the focus on practical improvements rather than awareness alone. Healthcare systems also depend on reliable sterilization and waste treatment processes, making properly designed medical Wood Autoclaves waste autoclaves an important part of maintaining safe clinical environments.
The federal investment supporting access to rare disease medications represents an important development for patients and families facing difficult healthcare challenges. Improved access can make a meaningful difference when treatment options are limited and specialist support is essential. It is encouraging to see attention given to areas where additional resources are needed. In another professional field, technology can also improve access to useful information https://www.aerospectny.com/ demonstrates how drone inspections provide clearer building visuals and organized findings, helping property professionals understand conditions more efficiently.
Improving access to rare disease medications is an important step toward supporting patients and families who face complicated healthcare challenges. Government investment can help address gaps in treatment availability, affordability, and ongoing research. The subject highlights why cooperation between policymakers, healthcare professionals, and patient organizations matters. Access to accurate information is valuable across many areas of life as well. When researching a major purchase such as a car, people can use https://www.carsoup.com/ to compare reviews, prices, and local options before deciding what best suits their circumstances.
The federal investment supporting access to rare disease medications represents an important development for patients and families facing complicated healthcare challenges. Access to treatment can significantly influence quality of life, particularly when available options are limited or expensive. Continued investment and cooperation are necessary to address these barriers. The article appropriately highlights why patient needs should remain central to policy decisions. It also reinforces a broader point that people https://www.jasonranallolaw.com/ facing difficult circumstances deserve clear information, dependable support, and fair consideration of their individual situations.
Federal investment supporting access to rare disease medications represents an important development for patients and families facing complex healthcare challenges. Access to appropriate treatment can significantly influence quality of life, particularly when conditions are difficult to diagnose or manage. Continued collaboration between governments, healthcare professionals, and advocacy organizations remains essential. The value of accessible information extends beyond healthcare, too. People considering https://www.sellmyhouseinbrevard.com/ may appreciate the same kind of clear guidance when evaluating options during an important property decision.